Neoadjuvant Treatments for Locally Advanced, Resectable Esophageal Cancer: A Network Meta-Analysis

Abstract

The relative survival benefits and post-operative mortality among the different types of neoadjuvant treatments (such as chemotherapy only, radiotherapy only or chemoradiotherapy) for esophageal cancer patients are not well established. To evaluate the relative efficacy and safety of neoadjuvant therapies in resectable esophageal cancer, a Bayesian network meta-analysis was performed.

MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched for publications up to May 2016. ASCO and ASTRO annual meeting abstracts were also searched up to the 2015 conferences. Randomized controlled trials that compared at least two of the following treatments for resectable esophageal cancer were included: surgery alone, surgery preceded by neoadjuvant chemotherapy, neoadjuvant radiotherapy or neoadjuvant chemoradiotherapy. The primary outcomes assessed from the trials was overall survival.

31 randomized controlled trials involving 5496 patients were included in the quantitative analysis. The network meta-analysis showed that neoadjuvant chemoradiotherapy improved overall survival when compared to all other treatments including surgery alone (HR 0.75, 95% CR 0.67 – 0.85), neoadjuvant chemotherapy (HR 0.83. 95% CR 0.70 - 0.96), and neoadjuvant radiotherapy (HR 0.82, 95% CR 0.67 – 0.99). However, the risk of postoperative mortality increased when comparing neoadjuvant chemoradiotherapy to either surgery alone (RR 1.46, 95% CR 1.00 – 2.14) or to neoadjuvant chemotherapy (RR 1.58, 95% CR 1.00 – 2.49).

In conclusion, neoadjuvant chemoradiotherapy improves overall survival but may also increase the risk of postoperative mortality in patients locally advanced resectable esophageal carcinoma. This article is protected by copyright. All rights reserved.

from Cancer via ola Kala on Inoreader http://ift.tt/2stHMOX
via IFTTT